Platelet test for finding and tracking prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial studies a new blood test that looks at platelets (a part of your blood) to help find prostate cancer or keep track of it. You may join if you are a man over 40 with a suspicion of prostate cancer who has not been treated for it before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 40 or older.
- You have signs or a doctor's suspicion of prostate cancer (but no prior diagnosis).
- You have not been treated for prostate cancer before.
- You do not have a severe clotting disorder that cannot be reversed.
- You have not taken aspirin, ibuprofen, clopidogrel, or similar blood-thinning medications in the past 7 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new blood test to help decide if you need a prostate biopsy. It may help men with high PSA levels or an abnormal rectal exam avoid unnecessary procedures.
This study uses a simple blood test to look for microRNA patterns that may help spot prostate cancer earlier and avoid unnecessary biopsies. If you have elevated PSA or suspicious findings, this test might give more information about your risk.
This study uses a new artificial intelligence test to look for tiny amounts of cancer DNA in your blood. It aims to help catch prostate cancer earlier, when it may be easier to treat.
This trial studies a blood test that looks for tumor DNA in men with high-risk or advanced prostate cancer. It may help doctors understand the cancer better and guide treatment decisions.
This study tests a new blood test (Proclarix) that may help doctors decide if a prostate biopsy is needed. It is for men with a slightly elevated PSA who are already considering a biopsy.
This study looks at whether a blood test that finds tiny amounts of remaining cancer (called minimal residual disease) can help predict how well treatment works for men with prostate cancer that has spread. If you qualify, you'll help researchers understand if this test can guide future treatment decisions.
Hear when a new Prostate Cancer (Diagnosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.